Shares of Waters Corporation (NYSE:WAT – Get Free Report) have been given an average rating of “Moderate Buy” by the twenty-one research firms that are presently covering the firm, MarketBeat.com reports. Nine analysts have rated the stock with a hold recommendation, nine have given a buy recommendation and three have issued a strong buy recommendation on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $401.60.
Several research firms have commented on WAT. The Goldman Sachs Group upped their price objective on shares of Waters from $380.00 to $425.00 and gave the company a “buy” rating in a report on Tuesday, July 14th. Guggenheim reaffirmed a “buy” rating and set a $440.00 target price on shares of Waters in a report on Wednesday, July 8th. Bank of America increased their price target on shares of Waters from $370.00 to $400.00 and gave the company a “neutral” rating in a report on Tuesday, June 2nd. Sanford C. Bernstein initiated coverage on shares of Waters in a research report on Friday, June 26th. They set an “outperform” rating and a $435.00 price objective for the company. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Waters in a report on Friday, July 17th.
Check Out Our Latest Analysis on WAT
Institutional Trading of Waters
Waters Stock Performance
Shares of NYSE WAT opened at $370.93 on Thursday. The company has a current ratio of 1.79, a quick ratio of 1.13 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $36.42 billion, a P/E ratio of 47.13, a P/E/G ratio of 2.22 and a beta of 1.20. Waters has a 12 month low of $275.05 and a 12 month high of $414.15. The stock has a 50 day moving average of $363.34 and a 200-day moving average of $345.93.
Waters (NYSE:WAT – Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $2.70 earnings per share for the quarter, beating analysts’ consensus estimates of $2.31 by $0.39. Waters had a return on equity of 15.60% and a net margin of 11.91%.The business had revenue of $1.27 billion for the quarter, compared to analysts’ expectations of $1.20 billion. During the same quarter in the prior year, the business earned $2.25 EPS. The firm’s revenue for the quarter was up 91.4% on a year-over-year basis. Waters has set its Q2 2026 guidance at 2.950-3.050 EPS and its FY 2026 guidance at 14.400-14.600 EPS. As a group, equities research analysts predict that Waters will post 14.51 EPS for the current year.
Waters Company Profile
Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.
Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.
Read More
- Five stocks we like better than Waters
- Could Truth API Become Trump Media’s First Meaningful Revenue Driver?
- Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying
- Moog Is More Than a Missile Maker, and Wall Street Is Noticing
- A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.
